Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $12.50 Average PT from Brokerages

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has been assigned an average recommendation of “Moderate Buy” from the five brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $12.50.

A number of research firms recently commented on AMRX. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, October 8th. Piper Sandler restated an “overweight” rating and issued a $13.00 price target (up previously from $11.00) on shares of Amneal Pharmaceuticals in a research report on Friday, October 31st. Finally, JPMorgan Chase & Co. increased their price objective on Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $11.94 on Friday. Amneal Pharmaceuticals has a 1 year low of $6.68 and a 1 year high of $12.68. The business’s fifty day moving average is $10.99 and its 200-day moving average is $9.37. The stock has a market cap of $3.75 billion, a PE ratio of 597.30 and a beta of 1.36.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, October 30th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.The business had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. Equities research analysts predict that Amneal Pharmaceuticals will post 0.53 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Nikita Shah sold 131,856 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the completion of the sale, the executive vice president directly owned 146,403 shares of the company’s stock, valued at $1,745,123.76. This represents a 47.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ted C. Nark sold 50,000 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $11.72, for a total value of $586,000.00. Following the completion of the transaction, the director owned 291,029 shares of the company’s stock, valued at $3,410,859.88. This trade represents a 14.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 231,856 shares of company stock worth $2,743,724 over the last ninety days. 26.56% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. CIBC Bancorp USA Inc. acquired a new stake in shares of Amneal Pharmaceuticals during the third quarter valued at approximately $161,000. Danske Bank A S purchased a new position in Amneal Pharmaceuticals during the 3rd quarter worth approximately $1,092,000. Advisory Services Network LLC purchased a new position in Amneal Pharmaceuticals during the 3rd quarter worth approximately $50,000. Caxton Associates LLP acquired a new stake in Amneal Pharmaceuticals during the 3rd quarter valued at $1,351,000. Finally, Westshore Wealth LLC acquired a new stake in Amneal Pharmaceuticals during the 3rd quarter valued at $13,833,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.